These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17786639)

  • 1. Understanding cooperativity in human p450 mediated drug-drug interactions.
    Sligar SG; Denisov IG
    Drug Metab Rev; 2007; 39(2-3):567-79. PubMed ID: 17786639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions.
    Tang W; Stearns RA
    Curr Drug Metab; 2001 Jun; 2(2):185-98. PubMed ID: 11469725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome-P450-Mediated Drug
    Steyn SJ; Varma MVS
    Mol Pharm; 2020 Aug; 17(8):3024-3032. PubMed ID: 32589434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical cytochrome p450 kinetics: implications for drug discovery.
    Tracy TS
    Drugs R D; 2006; 7(6):349-63. PubMed ID: 17073518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4.
    Isin EM; Guengerich FP
    J Biol Chem; 2007 Mar; 282(9):6863-74. PubMed ID: 17200113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug metabolism and drug interactions in the elderly.
    Herrlinger C; Klotz U
    Best Pract Res Clin Gastroenterol; 2001 Dec; 15(6):897-918. PubMed ID: 11866484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions.
    Crespi CL; Penman BW
    Adv Pharmacol; 1997; 43():171-88. PubMed ID: 9342176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical Michaelis-Menten kinetics in cytochrome P450 enzymes: A focus on substrate inhibition.
    Leow JWH; Chan ECY
    Biochem Pharmacol; 2019 Nov; 169():113615. PubMed ID: 31445022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cytochrome P450 enzymes in drug-drug interactions.
    Guengerich FP
    Adv Pharmacol; 1997; 43():7-35. PubMed ID: 9342171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3.
    van Vugt-Lussenburg BM; Damsten MC; Maasdijk DM; Vermeulen NP; Commandeur JN
    Biochem Biophys Res Commun; 2006 Aug; 346(3):810-8. PubMed ID: 16777067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically significant drug interactions.
    Johnson MD; Newkirk G; White JR
    Postgrad Med; 1999 Feb; 105(2):193-5, 200, 205-6 passim. PubMed ID: 10026713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterotropic cooperativity in oxidation mediated by cytochrome p450.
    Niwa T; Murayama N; Yamazaki H
    Curr Drug Metab; 2008 Jun; 9(5):453-62. PubMed ID: 18537580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.
    Morgan ET
    Clin Pharmacol Ther; 2009 Apr; 85(4):434-8. PubMed ID: 19212314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereoselectivity of human cytochrome p450 in metabolic and inhibitory activities.
    Niwa T; Murayama N; Yamazaki H
    Curr Drug Metab; 2011 Jul; 12(6):549-69. PubMed ID: 21476971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance.
    Johnson WW
    Drug Metab Rev; 2008; 40(1):101-47. PubMed ID: 18259986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism.
    Muruganandan S; Sinal CJ
    Clin Pharmacol Ther; 2008 Jun; 83(6):818-28. PubMed ID: 18388875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition.
    Niwa T; Yamazaki H
    Curr Drug Metab; 2012 Oct; 13(8):1145-59. PubMed ID: 22571484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of human cytochrome P450 enzymes.
    Guengerich FP
    FASEB J; 1992 Jan; 6(2):745-8. PubMed ID: 1537465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.